William Blair analyst Sami Corwin reiterated an Outperform rating on CRISPR Therapeutics (NASDAQ: CRSP)The analyst commented, "We continue to believe ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE